Advertisement|Remove ads.

Shares of UnitedHealth Group (UNH) have emerged as the biggest driver of the Dow Jones Industrial Average’s return toward 50,000, turning a battered healthcare giant into one of Wall Street’s hottest comeback trades.
UNH stock has surged 47% since Feb.10, making it the best-performing Dow component over the same period and outpacing even AI winners, including Amazon’s 31% gain, Caterpillar’s 22% rise, Nvidia’s 20% jump, and Cisco Systems’ 18% gain.
UnitedHealth entered the year under pressure after soaring medical costs, Medicare Advantage reimbursement changes, and a collapse in profit guidance rattled investors last year.
Now, the healthcare firm says a turnaround is coming earlier than expected. At Bank of America’s Healthcare Conference this week, CFO Wayne DeVeydt said that first-quarter results pointed to “a very strong year” if conditions hold. He said Optum Health, a major drag last year, is now “performing better than expected, sooner than expected.”
Optum Health posted $1.3 billion in adjusted operating profit with margins of 5.4%, ahead of analyst expectations. Bank of America Securities (BofA) later raised its price target on UNH shares to $420 from $380, implying a 5% upside from current levels. The bank cited “bullish” discussions at the conference, saying UnitedHealth is increasingly confident it can return most businesses to at least the low end of their target margin ranges by 2028.
The company is still working through fallout from Medicare Advantage changes that UnitedHealth previously said could create a $6 billion hit this year. UnitedHealth has responded by renegotiating contracts, trimming its workforce, reworking benefits and divesting clinics. The company said membership losses are now tracking in line with projections and not as severe as worst-case scenarios.
UnitedHealth’s rally has also picked up a political tailwind. U.S. President Donald Trump’s latest filings showed multiple UNH purchases during the first quarter, including a trade valued between $100,001 and $250,000 on Jan.23.
Additional filings showed smaller UNH purchases on Jan.12, Feb.23, March 17 and March 23, along with a separate purchase valued between $50,001 and $100,000 on March 18.
DeVeydt said UnitedHealth expects to invest $1.5 billion into AI this year and is already generating at least a two-to-one return on those investments, with payback periods under 12 months. “Our confidence level is growing by the day around the benefits we are seeing,” he said. The company said AI is central to redesigning healthcare administration, automating claims processing and simplifying prior authorization systems.
UnitedHealth has already rolled out AI-based tech across clinics, automated coding systems and real-time adjudication tools. The company also said it plans to reduce prior authorization requirements by 30% and process all authorizations in real time by the end of 2027.
The AI strategy centers around Optum Health and Optum Insight, which UnitedHealth sees as long-term growth engines capable of driving both margin expansion and new software revenue streams. Optum Rx recently unveiled a “transparent, fee-based” pricing model to move away from traditional rebates.
The move also comes as the pharmacy-benefit-manager industry faces mounting regulatory scrutiny over rebates and drug pricing. Meanwhile, the company plans to repurchase at least $2 billion of stock by the end of the second quarter under existing authorization.
On Stocktwits, retail sentiment was ‘bullish’ amid a 52% jump in message volumes over the past month.

One user said, “while companies that make AI chips are being rewarded in the market, the companies that actually USE AI chips to make the world a better place should likewise be rewarded!”
Another user said, “This was a $600 stock 18 months ago. So $400 is still a dip buy. It's all about paytience.”
UNH stock has risen 33% over the past year.
For updates and corrections, email newsroom[at]stocktwits[dot]com.
Read Next: ASTS, RKLB Stocks Get The Trump Pump After Hidden Space Stock Bets Emerge